Fragile X syndrome: Research & Drug Discovery Data

Drug discovery

drugs

With orphan designations

Overview

Fragile X syndrome (FXS) is a genetic disorder caused by a CGG trinucleotide repeat expansion (>200 repeats) in the FMR1 gene on the X chromosome, leading to reduced production of fragile X mental retardation protein (FMRP). This results in intellectual disability, developmental delays, autism spectrum features (33% of cases) [1][6], anxiety, ADHD, and characteristic physical traits (long face, large ears, macroorchidism) [1][6][16]. Males are typically more severely affected due to X-linked inheritance [12][17].

Population

Affects ~1:7,000 males and ~1:11,000 females [7][12][19]
Most common inherited cause of intellectual disability [7][16]
Carrier frequency: 1:150-300 females and 1:400-850 males [2][10]

Burden

Incremental annual healthcare costs: $33,409/person (Medicaid) [4][9]
35% require ER visits, 34% use home services, 25% need intensive therapies [4][9]
44% of caregivers report significant productivity loss [9][14]

Therapies

Multidisciplinary care: Speech-language, occupational, and physical therapies [3][16][18]
Pharmacotherapy: SSRIs (sertraline), stimulants (methylphenidate), and antipsychotics (aripiprazole) for anxiety, ADHD, and aggression [8][18]
Early intervention: Behavioral strategies and environmental modifications to enhance function [3][6][16]

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders

Research Papers

1,534 drug discovery papers related to Fragile X syndrome, with 6 first-in-class and 30 next-in-class early-stage therapies forecasted to outperform the average preclinical success rate. Recent publications:

2026-06-29 | Early life Oxytocin treatment Attenuates Seizure Susceptibility in Male, but not Female, Fmr1-KO Mice.

Fragile X syndrome (FXS) is the leading inherited cause of intellectual disability, and is frequently accompanied by seizures. Early-life treatment with the hormone oxytocin (OXT) improves social behavior and cognitive function in rodent models of autism with intellectual disability, including FXS, but potential OXT treatment effects on seizure susceptibility have not been evaluated. Here we tested, in both sexes, if intranasal OXT (iOXT) or saline (iSAL) during the second postnatal week reduces audiogenic seizures (AGS) in the Fmr1-Knockout (KO) mouse model of FXS. OXT given daily from postnatal day (P) 7 to P13 significantly reduced the incidence and severity of AGS and the latency to seize in adult male Fmr1-KOs. Female KOs exhibited less severe seizures that were unaffected by treatment. Wild type mice did not exhibit AGS independent of treatment. To test if antiepileptic effects of iOXT are age-dependent, a separate cohort received iOXT daily from P30 to P36. Male KOs receiving later treatments exhibited robust seizures that were comparable between OXT- and SAL-treatment groups, suggesting that OXT's enduring antiepileptic effects are confined to early postnatal treatments. Tests of acute OXT effects in adulthood demonstrated an attenuation of male Fmr1-KO AGS at testing 30-60 min and 1 day post-treatment but these effects were not evident 15 days later. These findings reveal marked sex differences in the propensity for audiogenic seizures in Fmr1-KO mice and demonstrate that early-life OXT treatment mitigates seizure susceptibility in males FXS model mice.

Open article ↗

2026-06-16 | The role of FMR1 mRNA structure on the efficiency of non-canonical translation of toxic polyglycine protein.

Repeat-associated non-AUG (RAN) translation of mutant FMR1 messenger RNA (mRNA) containing CGG repeat expansions results in the production of a toxic polyglycine protein (FMRpolyG), which contributes to fragile X premutation-associated conditions (FXPAC), including fragile X-associated tremor/ataxia syndrome (FXTAS). The 5' untranslated region of FMR1 mRNA folds into a thermodynamically stable secondary structure at the region of excessively expanded CGG repeats and constitutes a template for RAN translation initiated from near-cognate start codons located upstream of the CGGs. Cis-regulatory elements, including sequence context and stable secondary structures within mRNA, can affect translation initiation and elongation. Here, we show that different nucleotide sequence contexts close to the near-cognate start codon affect FMRpolyG synthesis. Moreover, the distance between the near-cognate start codon and downstream stable RNA structure considerably affects the efficiency of RAN translation initiation, which is positively correlated with the number of CGG repeats. In contrast, translation elongation is impaired as CGG repeats expand. We show that native FMRpolyG containing a short polyglycine tract is synthesized efficiently but rapidly degraded by the proteasome. Our results provide insight into the structural dependencies that regulate the translation of CGGs and can be used in other repeat expansion disorders. We also show that the RNA structure is a potential therapeutic target in FXPAC.

Open article ↗

2026-06-11 | The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis.

Striatal-Enriched Protein Tyrosine Phosphatase (STEP) constrains synaptic potentiation by dephosphorylating postsynaptic substrates, but its presynaptic role has remained unclear. Here, we identify a previously unrecognized function of STEP in regulating axonal differentiation and synapse assembly. Genetic and pharmacological manipulation of STEP in vivo and in vitro show that STEP limits presynaptic maturation by restricting synaptic vesicle protein clustering along developing hippocampal axons. Using a reconstituted circuit-on-a-chip we show that loss of presynaptic STEP is sufficient to significantly increase the number of axodendritic synapses. Functional imaging further revealed that the increased synaptic puncta observed in STEP KO neurons actively undergo depolarization-evoked vesicle exocytosis, representing bona fide functional synapses. Multielectrode array recordings reveal that STEP deletion increases neuronal excitability, and network synchrony, hallmarks of enhanced presynaptic efficacy. Mechanistically, these effects reflect sustained phosphorylation of STEP promoting presynaptic assembly and release competence. Importantly, inhibiting STEP also rescues presynaptic differentiation defects in Fmr1 KO neurons, implicating aberrant STEP signaling in Fragile X-associated synaptic pathology. Thus, STEP serves as a phosphatase gatekeeper that restrains presynaptic differentiation and neurotransmission, and its inhibition may offer a therapeutic strategy to correct synaptic deficits in Fragile X Syndrome.

Open article ↗

2026-06-29 | Early life Oxytocin treatment Attenuates Seizure Susceptibility in Male, but not Female, Fmr1-KO Mice.

Open article ↗

2026-06-16 | The role of FMR1 mRNA structure on the efficiency of non-canonical translation of toxic polyglycine protein.

Open article ↗

2026-06-11 | The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis.

Open article ↗

Access all drug discovery articles and probability of success in trials forecasts:

Request access

Drug Discovery Landscape

53 orphan drug designations for Fragile X syndrome.

Drug	Therapy type	Regulator	Orphan designation	Approval	Sponsor
alkanoylamine derivative selective modulator of a Class A G protein coupled receptor	small molecules	FDA	2025-11-19	—	GEXVal Inc.
(R)-3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1methylethyl)benzamide	small molecules	EMA	2025-06-20	—	Somerville Development Partners B.V.
3-Chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl) amino]methyl]piperidin-1-yl]methanone	small molecules	FDA	2025-02-28	—	Neurolixis, Inc.
small molecule modulator of large conductance, calcium-activated potassium (BK, KCa1.1) channels	small molecules	FDA	2024-11-19	—	Servier Pharmaceuticals LLC
3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone	small molecules	EMA	2024-11-11	—	Neurolixis
(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide	small molecules	FDA	2024-05-14	—	Spinogenix, Inc.
Zatolmilast	small molecules	EMA	2024-03-21	—	Shionogi B.V.
5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1’-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione	small molecules	EMA	2023-03-20	—	Quality Regulatory Clinical Ireland Limited
blarcamesine	small molecules	FDA	2022-11-03	—	Anavex Life Sciences Corp.
Lisuride Maleate	small molecules	FDA	2022-10-24	—	NeuroVenti Inc.
replication-incompetent adeno-associated virus serotype 9 vector encoding the human fragile x mental retardation 1 gene	gene therapies	FDA	2022-06-16	—	Cincinnati Children’s Hospital
Ibudilast	small molecules	FDA	2022-06-15	—	Healx Limited
4-(3-cyano-6-ethoxyquinolin-2-yl)-N- (2-fluorophenyl)-1,4-diazepane-1-carbothiomide	small molecules	FDA	2022-05-26	—	Neuronascent, Inc.
Ibudilast	small molecules	EMA	2022-05-16	—	Healx Technology Limited
Codergocrine mesilate, oxitriptan	small molecules	EMA	2022-03-16	—	Purposeful I.K.E.
Cannabidiol	small molecules	EMA	2022-02-24	—	QbD Flanders
Psilocybin	small molecules	FDA	2021-10-25	—	Nova Mentis Life Science Corp.
Psilocybine	small molecules	EMA	2021-10-15	—	Comac Medical Ltd.
2-[4-[3-(methylamino)-1-phenylpropoxy]phenyl]ethanol hydrochloride	small molecules	EMA	2021-05-20	—	Connecta Therapeutics S.L.
Sulindac	small molecules	FDA	2021-05-10	—	Healx Limited
Sulindac	small molecules	EMA	2020-12-09	—	Healx Technology Limited
Balipodect	small molecules	FDA	2019-06-13	—	Takeda Development Center Americas, Inc.
Balipodect	small molecules	EMA	2019-04-24	—	Takeda Pharma A/S
alpha tocopherol and ascorbic acid	small molecules	FDA	2019-03-28	—	GenCo Pharmaceuticals LLC
zatolmilast	small molecules	FDA	2018-03-26	—	Tetra Discovery Partners, Inc.
Cannabidivarin	small molecules	EMA	2018-02-22	—	Jazz Pharmaceuticals Ireland Limited
Gaboxadol	small molecules	FDA	2017-10-03	—	Healx Limited
5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1’-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione	small molecules	FDA	2017-06-12	—	Autifony Therapeutics Limited
Cannabidivarin	small molecules	FDA	2017-06-06	—	Jazz Pharmaceuticals Research UK Limited
N-[(1R)-1-phenylethyl]-6-{1H-pyrazolo[3,4-d]pyrimidin-4-yl}quinazolin-2-amine [SOL 784]	small molecules	EMA	2017-04-20	—	Propharma Group The Netherlands B.V.
Alpha-tocopherol and ascorbic acid	small molecules	EMA	2017-02-27	—	Advanced Medical Projects
ganaxolone	small molecules	FDA	2016-12-28	—	Marinus Pharmaceuticals
Pyridoxine and L-pyroglutamic acid	small molecules	EMA	2016-06-27	—	FGK Representative Service Ltd
cannabidiol	small molecules	FDA	2016-02-23	—	Harmony Biosciences Management, Inc.
(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	small molecules	FDA	2015-12-09	—	Centre National de la Recherche Scientifique (CNRS)
Glycyl-L-2-methylprolyl-L-glutamic acid	small molecules	EMA	2015-07-28	—	Voisin Consulting Life Sciences
bryostatin 1	small molecules	FDA	2015-03-31	—	Synaptogenix, Inc.
Tideglusib	small molecules	EMA	2015-03-19	—	AMO Pharma Limited
(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one	small molecules	EMA	2014-10-15	—	Centre National de la Recherche Scientifique (CNRS)
Acamprosate calcium	small molecules	EMA	2014-10-15	—	Veristat Spain S.L.
metadoxine	small molecules	FDA	2013-12-16	—	Alcobra, Inc.
Trofinetide	small molecules	FDA	2013-10-23	—	ACADIA Pharmaceuticals Inc.
acamprosate	small molecules	FDA	2013-03-25	—	Confluence Pharmaceuticals, LLC
Mavoglurant [AFQ056]	small molecules	EMA	2012-10-10	—	Novartis Europharm Limited
acetyl-l-carnitine	small molecules	FDA	2012-07-24	—	Leadiant Biosciences, Inc.
basimglurant	small molecules	FDA	2012-03-09	—	Hoffmann-La Roche, Inc.
(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester	small molecules	FDA	2011-10-12	—	Stalicla SA
R-baclofen	small molecules	EMA	2011-04-15	—	Lakeside Regulatory Consulting Services Ltd
R-4-amino-3-(4-chlorophenyl)butanoic acid	small molecules	FDA	2008-11-28	—	Clinical Research Associates, LLC
3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride	small molecules	FDA	2008-07-28	—	Seaside Therapeutics
Valproate	small molecules	FDA	2008-05-05	—	Neuropharm Ltd,
Fenobam hydrochloride	small molecules	FDA	2006-11-20	—	Neuropharm, Ltd.
guanfacine	small molecules	FDA	1999-08-05	—	Watson Laboratories, Inc.

Fragile X syndrome

Fragile X syndrome

Fragile X syndrome

Overview

Population

Burden

Therapies

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders

Research Papers

2026-06-29 | Early life Oxytocin treatment Attenuates Seizure Susceptibility in Male, but not Female, Fmr1-KO Mice.

2026-06-16 | The role of FMR1 mRNA structure on the efficiency of non-canonical translation of toxic polyglycine protein.

2026-06-11 | The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis.

2026-06-29 | Early life Oxytocin treatment Attenuates Seizure Susceptibility in Male, but not Female, Fmr1-KO Mice.

2026-06-16 | The role of FMR1 mRNA structure on the efficiency of non-canonical translation of toxic polyglycine protein.

2026-06-11 | The tyrosine phosphatase STEP is a developmental suppressor of synaptogenesis.

Drug Discovery Landscape

Updated: Jul 27, 2026